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ABSTRACT
We conducted this study to determine event-free and overall survival among women with hormone-insensitive
or hormone-resistant metastatic breast cancer receiving consolidation with high-dose chemotherapy (HDC)
and hematopoietic support versus no further chemotherapy after intensive induction chemotherapy. Eligible
patients received induction doxorubicin, 5-fluorouracil, and methotrexate (AFM) for 2 to 4 cycles. Women in
complete remission were randomized to immediate HDC with cyclophosphamide, cisplatin, and carmustine
followed by autologous hematopoietic support or to no further therapy. Patients on the observation arm of
therapy were offered salvage HDC at the time of relapse. Partial responders to AFM were offered immediate
HDC. A total of 425 patients were enrolled onto the study. The median event-free survival for women
randomized to induction therapy alone was 3.8 months, compared with 9.7 months for women who completed
HDC (P < .006). Of the patients randomized to observation, 5 (10%) of 51 remain event free, compared with
13 (26%) of 49 patients who underwent immediate HDC (P  .03). Of women converted to a complete
response by salvage HDC after a partial response to AFM, overall survival was similar to that in women
randomized to immediate HDC. Follow-up is now in excess of 5 years. The 5-year event-free survival is 15%
(95% confidence interval, 12%-18%), and the 5-year overall survival is 20% (95% confidence interval, 17%-
25%). Immediate HDC after a complete response to AFM produced some durable long-term responses in
hormone-insensitive/-resistant metastatic breast cancer. Salvage HDC converted 30% of partial responders to
complete responders with similar survivals. The addition of novel targeted therapies to intensive-dose che-
motherapy regimens may further improve survival in metastatic breast cancer.
© 2006 American Society for Blood and Marrow Transplantation
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chemotherapy ● Bone marrow transplantationresented at the San Antonio Breast Cancer Meeting, December 3, 1996.
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1NTRODUCTION
Breast cancer is the most common malignancy in
omen and is the second leading cause of cancer-
ssociated mortality [1]. Despite advances in treat-
ent, the prognosis for women with metastatic breast
ancer remains poor, with a median survival of 12 to
8 months [2-4]. The survival is shorter for the sub-
roup of hormone receptor–negative patients and for
atients whose hormonal therapy has failed; these pa-
ients have an 8- to 12-month median survival [3]. It is
nusual for a woman with hormone-insensitive meta-
tatic breast cancer to live for 5 years, especially pro-
ression free. Large series and meta-analyses have
emonstrated 10% 5-year survival for all patients
nd 5% 5-year survival for hormone receptor–nega-
ive patients [2-4]. Furthermore, long-term survival in
reast cancer, as in other cancers, has as a necessary,
ut not sufﬁcient, condition the achievement of com-
lete remission (CR), which is evident in both primary
nd metastatic disease.
Breast cancer is generally responsive to chemo-
herapy, with objective response rates between 50%
nd 90% in chemotherapy-naive metastatic breast
ancer [5-8]. However, standard chemotherapy, even
ith contemporary regimens, usually results in CRs in
20% of treated patients [5-8]. High-dose combina-
ion chemotherapy with hematopoietic support pro-
uces overall response rates up to 95%, with CR rates
etween 40% and 60% [9-13]. The improved survival
n women with metastatic breast cancer treated with
igh-dose chemotherapy (HDC) has been attributed
y some to selection of patients with fewer sites of
etastatic disease and improved performance status
14]. Few randomized trials have investigated HDC
ersus standard chemotherapy in patients with meta-
tatic breast cancer, and those that have been reported
re small or have had overall poor treatment results.
e performed a prospective, randomized study com-
aring consolidation with HDC with hematopoietic
upport versus no further chemotherapy in women
ith hormone-insensitive or hormone-resistant met-
static breast cancer in CR after intensive doxorubi-
in-based induction chemotherapy.
ETHODS
atients
A total of 425 patients were enrolled between May
988 and May 1995. All patients had biopsy-positive
easurable metastatic breast cancer (387 patients) or
nﬂammatory breast cancer (39 patients) and had not
eceived chemotherapy for metastatic disease. Patients
ere estrogen receptor (ER) and progesterone recep-
or (PR) negative or had experienced treatment failure
f at least 1 round of hormonal therapy if the tumor
as ER or PR positive before enrollment. e
96All patients underwent an extensive staging eval-
ation, including a computed tomographic scan of the
ead, chest, abdomen, and pelvis; bone scan; multiple
ated acquisition; pulmonary function tests; bilateral
one marrow aspirates and biopsies; creatinine clear-
nce; and routine blood work. Patients were eligible if
hey had a Karnofsky performance status of at least
0%; forced vital capacity, forced expiratory volume
n 1 second, and carbon monoxide diffusion in the
ung60% of predicted; left ventricular ejection frac-
ion 45% (lower limit of normal at our institution);
spartate aminotransferase and bilirubin 1.5 times
ormal; and creatinine clearance 60 mL/min. Pa-
ients were ineligible if they had an untreated central
ervous system metastasis; positive bone marrow as-
irate or biopsy on routine histology; 3 bone me-
astases; or positive -human chorionic gonadotropin,
uman immunodeﬁciency virus antibody, or hepatitis
surface antigen.
nduction Chemotherapy
Eligible patients received induction doxorubicin,
-ﬂuorouracil, and intermediate-dose methotrexate
AFM) as previously described [15]. The 5-ﬂuoroura-
il was given at a dose of 750 mg/m2 as a continuous
nfusion, days 1 to 5; doxorubicin 25 mg/m2 as an
ntravenous bolus, days 3, 4, and 5; and methotrexate
50 mg/m2 with folinic acid rescue on day 15. The
atients received the methotrexate only if their mu-
ositis and dermatologic toxicity were grade 3 ac-
ording to the common toxicity grading criteria. The
ncidence of grade 3 or 4 mucositis was high, so during
he study, a cohort of patients (n  60) was begun on
-ﬂuorouracil 500 mg/m2. Patients who received
-ﬂuorouracil 750 mg/m2 achieved a higher CR rate
han those who received 500 mg/m2 (30% versus
2%; P  .045; 2), so the dose was returned to 750
g/m2.
The patients received 2 to 4 (median, 4) cycles of
FM to the point of maximum response or a maxi-
um dose of doxorubicin 500 mg/m2 for patients who
ad received prior adjuvant doxorubicin. The design
f the trial called for randomization at the point of
R, without additional cycles of AFM, notwithstand-
ng the cumulative doxorubicin exposure at the time of
aximum response.
valuation
The patients underwent a repeat staging evalua-
ion, including a physical examination and computed
omographic scan of the chest, abdomen, and pelvis,
fter the second and each subsequent cycle of AFM
hemotherapy. The response to induction AFM was
etermined by using standard criteria, with the sum
otal of the perpendicular products of measurable dis-
ase used as the determinant of response. The re-
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High-Dose Chemotherapy for Breast Cancer
Bponses were scored at a group meeting, which in-
luded an independent radiologist. Eight patients with
minimal or indeterminant site of disease initially
valuated as partial response were converted to a CR
y either surgical resection or radiation therapy and
ere then randomized per protocol.
To validate the accuracy of the data, an indepen-
ent audit of the data from randomized patients was
ndertaken. Patient charts and radiographs were re-
iewed to verify patient demographics, sites of disease,
hemotherapy treatments, treatment responses, and
imes to relapse and death. Two cases were identiﬁed
n which the information extracted during this inde-
endent review differed from the initial evaluations.
hese differences were evaluated and resolved. This
nalysis used the audited and reconciled database.
andomization and Treatment Methods
Patients evaluated as having a CR after AFM in-
uction therapy were randomized either to immediate
DC and hematopoietic support or to AFM induc-
ion alone (observation). Patients randomized to ob-
ervation who subsequently relapsed were offered
reatment with the same HDC and hematopoietic
upport as salvage therapy at the time of relapse (im-
ediate versus salvage transplantation) and were fol-
owed up for response and survival.
Patients who were evaluated as achieving a partial
esponse after AFM induction therapy were treated
ith immediate consolidation with HDC and hema-
opoietic support. The patients whose disease did not
espond or progressed on AFM induction were not
onsidered appropriate for HDC on this trial.
one Marrow Harvest
After AFM induction chemotherapy and hemato-
oietic recovery to a leukocyte count 3000/L, pa-
ients randomized to HDC underwent a bone marrow
arvest, as previously described [16]. Brieﬂy, the bone
arrow was obtained from the posterior iliac crests by
sing multiple aspirations, with a minimum goal of 1
108 nucleated cells per kilogram. The patients ran-
omized to AFM induction alone (observation) also
nderwent the bone marrow harvest immediately after
andomization.
eukapheresis
After the bone marrow harvest, patients under-
ent cytokine priming to mobilize peripheral blood
rogenitor cells. The use of cytokine priming evolved
uring the study, and at different times, patients re-
eived granulocyte-macrophage colony-stimulating
actor, granulocyte colony-stimulating factor, or in-
erleukin 3. The patients were cytokine-primed on
everal growth factor studies [17]. Each cytokine-
rimed patient underwent 1 to 3 leukaphereses, until f
B&MTollection of a minimum of 1  1010 mononuclear
ells. CD34 enumeration was not generally used dur-
ng the time frame of this study as a guide for the
umber or duration of leukaphereses.
igh-Dose Chemotherapy
The patients received high-dose cyclophospha-
ide, cisplatin, and carmustine, the STAMP 1 regi-
en developed by Eder et al. [18]. The cyclophosph-
mide was administered intravenously over 1 hour at
875 mg/m2/d, days 6, 5, and 4. The cisplatin
as administered as a continuous infusion at 55 mg/
2/d on days 6, 5, and 4. The carmustine was
dministered as a 2-hour infusion at 600 mg/m2 on
ay 3. The doses of chemotherapy were adjusted to
he mean of the actual weight and ideal body weight
y using the New York Life Insurance Company Ta-
le for patients with an actual weight 20% above
heir ideal body weight. Patients who weighed 20%
bove their ideal body weight received chemotherapy
oses based on their actual weight.
one Marrow and Peripheral Blood Progenitor
ell Infusions
The bone marrow was thawed rapidly in a 37°C
ater bath at the bedside and infused over 15 to 30
inutes through the central venous access catheter.
he bone marrow was infused on day 	1. The pe-
ipheral blood progenitor cells were thawed in a similar
ashion at the bedside. Equal aliquots of peripheral blood
rogenitor cells were infused on days 1, 0, and 	1.
onsolidative Radiation Therapy or Surgery
After completion of HDC, patients were intended
o receive consolidation radiation therapy to pretreat-
ent sites of bulk disease in excess of 3 cm where
ossible. A small number of patients underwent sur-
ical consolidation, and they included patients with a
esidual single lung (n  1) or liver (n  2) metastasis
r those with modiﬁed radical mastectomy for women
ith inﬂammatory breast carcinoma (n  7). Of the
ther 32 patients with inﬂammatory breast cancer, 20
id not proceed to HDC (9 had progressive disease,
nd 11 refused or had excessive pre-HDC toxicity),
nd 12 had mastectomy before HDC.
The radiation therapy was delivered in an attempt
o sterilize the residual metastatic focus and is de-
cribed in detail elsewhere [19]. Radiation therapy was
redominantly administered to soft tissue disease,
uch as the chest wall or lymph nodes. Visceral dis-
ase, such as lung or liver metastases, was rarely con-
olidated with radiation therapy.
tatistical Methods
The primary end point for this study was event-
ree survival among randomized patients in an intent-
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1o-treat analysis. In addition, the overall survival for
ll patients enrolled and after immediate or salvage
ransplantation, as well as for the patients in partial
emission after AFM induction, was determined by
sing the Kaplan-Meier product-limit method [20].
he crossover design for high-dose consolidation
onfounds the interpretation of overall survival be-
ween the 2 randomized groups and essentially com-
ares immediate versus salvage transplantation, be-
ause both groups were prescribed to receive the same
DC. The log-rank test was used to compare the
verall or event-free survivals [21]. Event-free survival
as calculated from the ﬁrst cycle of AFM chemother-
py to disease progression (relapse) or death due to
ny reason, whichever occurred ﬁrst. Patients who
ere alive and disease free were censored at the date of
he last follow-up visit. Overall survival was calculated
rom the time of the ﬁrst cycle of AFM chemotherapy
o death, and patients who were alive were censored at
he date of last follow-up. The event-free and overall
urvival durations were calculated from the date of
andomization for the analysis of the complete re-
ponders.
ESULTS
atient Characteristics
A total of 425 patients were enrolled on the AFM
andomized study. The study is mature for a study of
etastatic breast cancer, with a median follow-up of
able 1. Patient Characteristics
Variable Data
ge, y, mean (range) 43 (24-64)
ace
White 384 (90.4%)
Black 36 (8.4%)
Hispanic, Asian, or Native American 5 (1.2%)
R
Positive 114 (27%)
Negative 311 (73%)
R
Positive 124 (29%)
Negative 301 (71%)
rior adjuvant chemotherapy
Yes 271 (65%)
No 143 (35%)
djuvant doxorubicin
Yes 53 (13%)
No 366 (87%)
ime from diagnosis to first metastatic
disease, mo, median (range) 16 (0-147)
isceral metastases
Yes 283 (69%)
No 128 (31%)
iver metastases
Yes 147 (35%)
No 278 (65%)0.6 years for all patients and 11.4 years for random- *
98zed patients. The patient characteristics for the entire
tudy and its major subgroups are listed in Table 1.
he average age of the patients was 43 years, with a
ange of 24 to 64 years. Ninety percent of the patients
ere white, 9% were black, and 1% were Asian, His-
anic, or Native American. The pretreatment disease
haracteristics were indicative of a poor prognosis for
he treatment group. Most patients had hormone re-
eptor–negative tumors, and the remainder had expe-
ienced disease progression during at least 1 hormonal
ntervention. There were 268 (63%) patients with
oth ER- and PR-negative tumors. In addition, 69%
ad measurable visceral metastatic disease, and 35%
ad hepatic metastases. Most patients (271/414; 66%)
ad experienced disease progression after receiving
djuvant chemotherapy. The study included 45 (11%)
atients whose initial presentation of breast cancer
as with metastatic disease and 39 (9%) whose initial
resentation was with stage IIIB inﬂammatory breast
ancer.
esponse to AFM Induction Chemotherapy
The AFM induction chemotherapy was an active,
lbeit toxic, standard-dose regimen, with an overall
esponse rate of 75%: there were 113 (27%) complete
esponders and 202 (48%) partial responders. Of the
emaining 110 patients, 39 (9%) patients had no re-
ponse, 44 (10%) patients had progression of disease
n AFM chemotherapy, and 27 (6%) were not evalu-
ble for response to AFM chemotherapy; most of
hese patients were not considered evaluable because
hey withdrew from the protocol during induction
hemotherapy. The factors predicting a response to
FM chemotherapy are presented elsewhere [22].
Table 2 lists the percentage of responders to AFM
hemotherapy with different sites of metastatic in-
olvement. In addition, Table 2 lists the pathologic
esponses for the patients with inﬂammatory breast
ancer who had a clinical CR to AFM and subse-
uently underwent mastectomy. Patients with lung or
iver metastases were less likely to respond to AFM
hemotherapy than were patients with soft tissue dis-
ase.
able 2. Response to AFM According to Site of Disease
Metastatic Site* n
Response to AFM
(CR  PR/total)
ymph nodes and chest wall 308 102  142/308 (79%)
ung/pleura 180 32  97/180 (72%)
iver 147 20  82/147 (69%)
nflammatory 39 12  18/39 (77%)
athologic complete response 39 1/39 (2%)
otal 425 113  202/425 (74%)
R indicates partial response.
Note that patients can have more than one site of metastasis.
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High-Dose Chemotherapy for Breast Cancer
Bomplete Responders
One hundred thirteen (27%) of the 425 patients
ad a CR to AFM chemotherapy (the median number
f cycles of AFM was 4 for both the immediate treat-
ent group and the delayed treatment group). One
undred of the 113 patients were randomized. Thir-
een patients who achieved a CR were not random-
zed: 6 patients with stage IIIB breast cancer achieved
clinical CR but had residual disease at surgical eval-
ation and therefore were considered medically ap-
ropriate for immediate high-dose consolidation, 1
eveloped rapidly progressive disease, 2 refused ran-
omization, and 4 were refused insurance coverage for
DC.
Of the 100 randomized patients, 49 were random-
zed to immediate transplantation and 51 to observa-
ion. The disease characteristics of the 113 complete
esponders are listed in Table 3. These characteristics
ere balanced between the randomized arms. The
rimary end point of the AFM randomized study was
he determination of the difference in event-free sur-
ival as a result of consolidation with HDC and he-
atopoietic support. The median event-free survival
or the women who were randomized to induction
herapy alone was 3.8 months and was signiﬁcantly
horter compared with 9.7 months for women ran-
omized to immediate consolidation with HDC and
ransplantation (log-rank test; P .006). The Kaplan-
eier curve for event-free survival for the randomized
omplete responders is shown in Figure 1.
Of the 51 patients in CR randomized to induction
herapy alone (AFM alone), 5 patients have not expe-
ienced disease progression, with times from random-
zation of 11, 8, 6, 6, and 5 years. Three patients who
ave not experienced disease recurrence 11, 8, and 6
ears after AFM had metastatic disease isolated to the
upraclavicular lymph nodes and have never received
adiotherapy. The other patient who was progression
ree at 6 years presented with a large primary tumor
nd had supraclavicular adenopathy at the time of
resentation. The ﬁnal patient had biopsy-positive
able 3. Disease Characteristics of the Complete Responders
Variable
Complete Responders
to AFM (n  113)
Yes No
R or PR positive 48 (42%) 65 (58%)
djuvant chemotherapy 54 (48%) 59 (52%)
iver metastases 20 (18%) 93 (82%)
ung metastases 32 (28%) 81 (72%)
ultiple (>2) sites of metastasis 53 (47%) 60 (53%)
urgery to CR 6 (5%) 107 (95%)
adiotherapy to CR 2 (2%) 111 (98%)
etastatic disease at presentation 18 (16%) 95 (84%)
nflammatory disease at presentation 12 (11%) 101 (89%)iver metastases and remains event free 5 years after d
B&MTandomization to observation. Of the 49 patients in
R randomized to immediate high-dose consolidation
AFM followed by cyclophosphamide, cisplatin and
CNU [CPB] plus autologous bone marrow trans-
lantation [ABMT]), 13 patients have not experienced
isease progression, with a time from randomization
f 5 to 12 years.
verall Survival
Because of the poor prognosis of women with
etastatic breast cancer whose disease progresses after
oxorubicin-based chemotherapy, patients were of-
ered salvage treatment with HDC with hematopoi-
tic support at the time of disease progression for
omen who were randomized to AFM alone. This
rotocol design allows the comparison of survivals of
mmediate consolidation versus salvage high-dose
onsolidation for patients in CR. Forty-three of the
omen whose disease progressed after the AFM alone
ere treated with salvage HDC with hematopoietic
upport by using the same high-dose CPB and ABMT
egimen that was prescribed for the patients who had
mmediate consolidation. Twenty-ﬁve (58%) of these
omen were converted by HDC into CR. The other
women who had progressive disease after AFM
lone refused HDC.
As shown in Figure 2, the overall survival of the
omen in CR randomized to immediate high-dose
onsolidation was similar to the overall survival of
omen randomized to observation, most of whom had
DC as salvage treatment after disease progression.
lthough patients who had salvage treatment trended
oward a longer median overall survival (3.3 versus 2.1
ears), the log-rank comparison was not statistically
ifferent (P  .20). There were no differences in the
edian overall survival of the 43 women who under-
ent delayed HDC versus that of the 49 women who
ad immediate HDC (P  .69).
EFS: Randomized Patients
Years from Randomization
P
ro
po
rti
on
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0.
0
0.
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0.
4
0.
6
0.
8
1.
0
p=0.006
Salvage TX
Immediate TX
N= 51
N= 49
Events= 45
Events= 36
Median= 0.32
Median= 0.81
igure 1. Event-free survival (EFS): randomized patients. TX in-
icates therapy.
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2artial Responders
One-hundred ninety-three (96%) of the 202 par-
ial responders to AFM induction chemotherapy pro-
eeded with HDC with hematopoietic support. HDC
as able to convert 58 patients (30%) to CR from the
est response of partial remission achieved from stan-
ard-dose therapy. In Figure 3, patients with the best
esponse to induction therapy of partial response had
n inferior overall survival compared with patients
ho achieved a CR after induction therapy. However,
he partial responders to AFM induction chemother-
py who were converted to complete responders with
DC had a long-term overall survival similar to that
f women who were complete responders to induction
hemotherapy and received consolidation with HDC,
s shown in Figure 4. In contrast, the patients who
ere not converted into CR had a 5-year overall
urvival of 5%.
OS: Randomized Patients
Years from Randomization
P
ro
po
rti
on
0 2 4 6 8 10 12 14
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
p=0.20
Salvage TX
Immediate TX
N= 51
N= 49
Events= 33
Events= 36
Median= 3.26
Median= 2.11
igure 2. Overall survival (OS): randomized patients. TX indicates
herapy.
OS: By Response to AFM
Years from Cycle 1 AFM
P
ro
po
rti
on
0 2 4 6 8 10 12 14
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
PR
CR
N= 202
N= 113
Events= 168
Events= 78
Median= 1.82
Median= 2.6
igure 3. Overall survival (OS) by response to AFM. PR indicates
artial response.
00verall and Event-Free Survival of All 425
atients
We have follow-up in excess of 5 years on all 425
omen who were enrolled on the trial. The median
vent-free survival is 10.3 months, and the median
verall survival is 21 months. More importantly, the
-year event-free survival is 15% (95% conﬁdence
nterval, 12%-18%), and the overall survival is 20%
95% conﬁdence interval, 17%-25%).
reatment-Associated Mortality
The AFM randomized protocol took 7 years to
omplete. In the ﬁrst 2 years of the study, the patients
eceived only bone marrow support (n  68); subse-
uent patients received both bone marrow and pe-
ipheral blood progenitor cells as support (n  218).
he treatment-associated mortality for the 286
omen who received HDC was 8.6% (n  25). The
auses of the treatment-associated mortality are listed
n Table 4. The 3 most common causes of treatment-
ssociated mortality were interstitial pneumonitis, in-
ection, and multiorgan failure, which included veno-
cclusive disease.
OS: By Response
Years from Cycle 1 AFM
P
ro
po
rti
on
0 2 4 6 8 10 12 14
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
CR Immediate TX
PR -> PR
PR -> CR
N= 49
N= 135
N= 58
Events= 36
Events= 122
Events= 37
Median= 2.34
Median= 1.52
Median= 3.16
igure 4. Overall survival (OS) by response. TX indicates therapy;
R, partial response.
able 4. Treatment-Associated Mortality
Cause n
% Treatment-
Associated Deaths
nfection 7 28%
Fungal (n  3)
Viral (n  2)
Bacterial (n  2)
ung toxicity 9 36%
TP/HUS 3 12%
ultiorgan failure/VOD 2 8%
emorrhage 4 10%
otal 25 100%
TP/HUS indicates thrombotic thrombocytopenic purpura and
hemolytic uremic syndrome; VOD, vero-occlusive disease.
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High-Dose Chemotherapy for Breast Cancer
BISCUSSION
We hypothesized in the conduct of this trial that
ong-term, disease-free, and overall survival in breast
ancer without continuous treatment depends on the
bility of the treatment to produce a CR and that
tandard-dose chemotherapy and HDC would com-
lement each other toward the achievement of that
oal. We performed a large prospective, randomized
tudy of HDC with hematopoietic support among
omen with poor-prognosis hormone-insensitive/-re-
istant measurable metastatic breast cancer. Our study
as designed to answer 3 questions: (1) Does consol-
dation with HDC improve event-free survival for
omen with poor-prognosis metastatic breast cancer
ho achieve a CR with intensive doxorubicin-based
hemotherapy (event-free survival as a primary end
oint is important to assess patients who do not need
DC or further therapy to maintain CR)? (2) Among
omen with poor-prognosis breast cancer who relapse
rom CR after intensive doxorubicin therapy, will sal-
age therapy with HDC produce long-term remis-
ions compared with immediate high-dose consolida-
ion? and (3) Among women who achieve a partial
esponse with intensive doxorubicin therapy, will
DC convert patients into durable CRs?
Evaluation of the study results was undertaken
ith recognition of the unique constraints of the tim-
ng of the study and the study design. Advances in the
cience of blood and marrow transplantation occurred
ver the several years the study was open. An equal
umber of patients in the immediate-treatment and
elayed-treatment arms received peripheral blood
rogenitor cells or bone marrow alone. Patients en-
olled in the study met strict criteria for inclusion. A
ossible selection bias should not inﬂuence the results
f the study because all patients who underwent ran-
omization were subject to the same rigorous screen-
ng for inclusion in the study. The study design did
ot include a nontransplantation, or “conventional,”
reatment arm.
The trial produced some noteworthy results. In-
ensive induction therapy with AFM produced fre-
uent CRs (27%). HDC with hematopoietic support
igniﬁcantly prolonged the event-free survival in
omen who were complete responders compared with
nduction chemotherapy alone, and disease-free sur-
ival longer than 7 years was possible in 27% of the
atients treated with this approach. HDC at the time
f disease progression for patients who were random-
zed to observation produced long-term survival
quivalent to that of patients who underwent imme-
iate transplantation. Finally, partial responders who
ere converted to complete responders with HDC
ad a long-term survival equivalent to that of patients
ho were complete responders to induction therapy. 4
B&MThe importance of CR in event-free survival and
verall survival has been previously reported [23,24].
The prognosis for women with metastatic breast
ancer remains unsatisfactory. Clinical trials of the
est available standard chemotherapy all have pro-
uced 10% 5-year survival, particularly if one fo-
uses on patients similar to the women treated on the
FM randomized protocol, ie, those with hormone-
nsensitive or hormone-resistant disease and with
ultiple sites of disease [25,26].
Randomized clinical trials investigating the role of
DC versus standard chemotherapy for women with
etastatic breast cancer present a variety of outcomes
ut few long-term follow-up data. Stadtmauer et al.
27] found no advantage for untreated metastatic
reast cancer patients consolidated with high-dose
yclophosphamide, thiotepa, and carboplatin versus
ontinuation of standard chemotherapy with long-
erm cyclophosphamide, methotrexate and 5-ﬂuorou-
acil (CMF) (24 months) after induction therapy with
yclophosphamide doxorubicin and 5-ﬂuorouracil
CAF) or CMF. Signiﬁcant results from this trial in-
luded a low CR rate to induction therapy (11%), few
omplete responses after HDC (13%), few patients
onverted from partial response to CR with HDC
6%), a short median follow-up (3 years), and a high
ropout rate after induction therapy and randomiza-
ion (46%).
Berry et al. [28] compared data from patients who
eceived standard-dose chemotherapy on Cancer and
eukemia Group B trials with data from the Autolo-
ous Blood and Marrow Transplant Registry to assess
verall survival. After controlling for known prognos-
ic factors in the data sets, they found a higher prob-
bility of 5-year survival (23% versus 15%) in women
ho received HDC compared with women who re-
eived standard-dose chemotherapy (P  .03).
A retrospective analysis of data from the European
roup for Blood and Marrow Transplantation for
atients with metastatic breast cancer who underwent
DC from 1990 to 1999 demonstrated signiﬁcant
esults. In this data set, patients who underwent trans-
lantation in CR had a 29% 5-year progression-free
urvival, with a 5-year progression-free survival of
8% for all patients evaluated; the 5-year overall sur-
ival for the entire cohort was 27%. The mortality
ate for patients treated in the metastatic setting was
% [29].
Several recent studies have reported improve-
ents in event-free survival and overall survival with
ouble or tandem transplantation. Sayer et al. [23]
reated 22 patients with doxorubicin and paclitaxel as
nduction followed by 2 cycles of high-dose doxoru-
icin, paclitaxel, cyclophosphamide, and thiotepa with
eripheral blood progenitor cell support. They re-
orted an initial response rate of 38.1% CR and
7.6% partial response, with overall survival of 19.0%
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2t a median follow-up of 36 months. There were no
oxic deaths on study. Somolo et al. [24] treated 29
atients with metastatic breast cancer by using tandem
ycles of cisplatinum and melphalan with peripheral
lood progenitor cell support. The CR rate for
omen with stage IV breast cancer increased from
8% after 1 cycle to 55% after both cycles. The
rojected 5-year progression free rate for these pa-
ients is 35%, and the projected overall survival rate is
1%. In a report of 3 sequential trials that used tan-
em transplantation, Elias et al. [30] reported re-
ponse rates of 53% to 76%. The median event-free
urvival for the 3 trials ranged from 39 to 98 months.
he actuarial 5-year overall survival rates for these
atients from the time of induction chemotherapy
ere 29%, 28%, and 50% for the 3 trials reported.
With the median follow-up for all patients now at
0.6 years, the AFM randomized trial provides evi-
ence for clinically meaningful long-term survival in
xcess of 20% for patients with hormone-insensitive
etastatic breast cancer after HDC. These ﬁndings,
owever, are with signiﬁcant toxicity. The AFM in-
uction therapy produced signiﬁcant mucositis and
eutropenia, and 30% of the patients experienced
emporary pulmonary toxicity that necessitated corti-
osteroids. The HDC was associated with an 8.6%
reatment-related mortality, although improvements
n supportive care measures offer the opportunity for
ecreased mortality rates.
In combination with new treatment strategies, in-
luding improved induction chemotherapy regimens,
iological and immunologic therapy, and encouraging
ata from the tandem-transplantation studies, HDC
ay continue to provide a platform for further re-
earch toward improvement in the survival of breast
ancer patients.
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